Literature DB >> 19075742

Phosphorothioate-stimulated cellular uptake of siRNA: a cell culture model for mechanistic studies.

A Detzer1, M Overhoff, A Mescalchin, M Rompf, G Sczakiel.   

Abstract

The phosphorothioate(PS)-stimulated cellular uptake of naked short interfering RNA (siRNA) into mammalian cells indicates a promising new mechanistic strategy because it makes use of a caveosomal, rather than an endosomal pathway, which is used by the majority of known delivery systems. This PS-stimulated mode delivers large amounts of siRNA primarily into the perinuclear space which is related to measurable though moderate target suppression. The observed limited efficacy seems to be related to intracellular trapping of siRNA. Here, we studied the intracellular localisation of siRNA and Argonaute 2 (Ago2), the major component of the RNA interference (RNAi) machinery, by density gradient centrifugation and fluorescence microscopy after PS-stimulated delivery or transfection with Lipofectamine 2000. The two cell lines ECV-304 and SKRC-35 both take up siRNA in the PS-stimulated mode but only ECV-304 shows RNAi, i.e. siRNA-mediated suppression of lamin A/C expression, whereas SKRC-35 does not. This lack of RNAi in the latter cell line seems to be due to a block of an intracellular siRNA translocation process. This study provides strong evidence for the view that co-localisation of siRNA and Ago2 in the vicinity of the rough endoplasmic reticulum (rER) in ECV-304 cells is related to target inhibition, whereas density gradient fractionation of cell organelles shows a lack of co-localisation in SKRC-35 cells in which RNAi does not occur after the PS-mediated delivery. In summary, we propose to exploit this dual cell system to identify important steps of intracellular trafficking of siRNA after PS mediated delivery that are crucial for its biological activity and which seem to be of general importance for the understanding of the intracellular trafficking and release of siRNA.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19075742     DOI: 10.2174/138161208786898770

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  11 in total

Review 1.  Strategies for targeted nonviral delivery of siRNAs in vivo.

Authors:  Sang-Soo Kim; Himanshu Garg; Anjali Joshi; N Manjunath
Journal:  Trends Mol Med       Date:  2009-10-19       Impact factor: 11.951

Review 2.  New short interfering RNA-based therapies for glomerulonephritis.

Authors:  Hideki Shimizu; Toshiro Fujita
Journal:  Nat Rev Nephrol       Date:  2011-05-24       Impact factor: 28.314

Review 3.  siRNA delivery to the lung: what's new?

Authors:  Olivia M Merkel; Israel Rubinstein; Thomas Kissel
Journal:  Adv Drug Deliv Rev       Date:  2014-06-05       Impact factor: 15.470

Review 4.  Oligonucleotide therapeutics in neurodegenerative diseases.

Authors:  Daniel R Scoles; Stefan M Pulst
Journal:  RNA Biol       Date:  2018-06-01       Impact factor: 4.652

5.  Selection, optimization, and pharmacokinetic properties of a novel, potent antiviral locked nucleic acid-based antisense oligomer targeting hepatitis C virus internal ribosome entry site.

Authors:  Carl Laxton; Kevin Brady; Sterghios Moschos; Paul Turnpenny; Jaiessh Rawal; David C Pryde; Ben Sidders; Romu Corbau; Chris Pickford; E J Murray
Journal:  Antimicrob Agents Chemother       Date:  2011-04-18       Impact factor: 5.191

6.  SiRNAs with Neutral Phosphate Triester Hydrocarbon Tails Exhibit Carrier-Free Gene-Silencing Activity.

Authors:  Matthew L Hammill; Kouta Tsubaki; Lidya Salim; Andrew J Varley; Ifrodet Giorgees; Mitsuru Kitamura; Tatsuo Okauchi; Jean-Paul Desaulniers
Journal:  ACS Med Chem Lett       Date:  2022-03-14       Impact factor: 4.632

7.  Preparation of novel curdlan nanoparticles for intracellular siRNA delivery.

Authors:  Jingfen Han; Jia Cai; Wuyinga Borjihan; Tsogzolmaa Ganbold; Tariq M Rana; Huricha Baigude
Journal:  Carbohydr Polym       Date:  2014-10-05       Impact factor: 9.381

8.  Cell stress is related to re-localization of Argonaute 2 and to decreased RNA interference in human cells.

Authors:  Anke Detzer; Christina Engel; Winfried Wünsche; Georg Sczakiel
Journal:  Nucleic Acids Res       Date:  2010-12-08       Impact factor: 16.971

Review 9.  Peptide-mediated cellular delivery of oligonucleotide-based therapeutics in vitro: quantitative evaluation of overall efficacy employing easy to handle reporter systems.

Authors:  S D Laufer; T Restle
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

10.  siRNAmod: A database of experimentally validated chemically modified siRNAs.

Authors:  Showkat Ahmad Dar; Anamika Thakur; Abid Qureshi; Manoj Kumar
Journal:  Sci Rep       Date:  2016-01-28       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.